Vasculitis: Diagnostic Workup and Treatment Plan
Initial Diagnostic Approach
For suspected vasculitis, immediately perform ANCA testing using antigen-specific ELISA (for both PR3-ANCA and MPO-ANCA) as the primary diagnostic method, and obtain tissue biopsy from the affected organ to confirm the diagnosis before initiating treatment. 1
Key Diagnostic Steps
ANCA Testing:
- Use high-quality antigen-specific ELISA for PR3-ANCA and MPO-ANCA as first-line testing (not indirect immunofluorescence) 1
- ANCA testing should only be performed when clinical features suggest vasculitis 2
- A positive ANCA strongly supports the diagnosis but does not replace biopsy confirmation
Tissue Biopsy:
- Biopsy is strongly recommended to establish new diagnosis and evaluate suspected relapses 3, 1
- Histopathological evidence (fibrinoid necrosis, pauci-immune glomerulonephritis, or granulomatous inflammation) remains the gold standard 2
- Diagnostic yield exceeds 70% when appropriate tissue is sampled 2
- For temporal arteritis, obtain at least 1 cm of temporal artery; treatment should not be delayed while awaiting biopsy 4
Baseline Assessment:
- Structured clinical examination of all organ systems at each visit 2
- Urinalysis (essential for detecting glomerulonephritis and monitoring for cyclophosphamide-related bladder toxicity) 2
- Serum creatinine, inflammatory markers (ESR, CRP)
- Chest imaging if pulmonary involvement suspected
Critical Pitfall: Do not delay treatment for life-threatening manifestations while awaiting biopsy results. Start high-dose glucocorticoids immediately if giant cell arteritis with visual symptoms is suspected 4.
Treatment Algorithm
Step 1: Categorize Disease Severity
Organ-threatening/Life-threatening disease includes: 2, 1
- Glomerulonephritis
- Pulmonary hemorrhage
- Central nervous system involvement
- Cardiac involvement
- Mesenteric involvement
- Mononeuritis multiplex
- Retro-orbital disease
Non-organ-threatening disease includes:
- Nasal/sinus disease without bony erosion
- Non-ulcerating skin involvement
- Myositis (skeletal muscle only)
- Non-cavitating pulmonary nodules
- Episcleritis
Step 2: Remission Induction Treatment
For Organ-threatening/Life-threatening GPA or MPA:
Use rituximab plus glucocorticoids as first-line therapy (rituximab is preferred over cyclophosphamide, especially in relapsing disease). 1
- Rituximab: Standard dosing per protocol
- Glucocorticoids: Start with 50-75 mg prednisolone equivalent daily (based on body weight), taper according to structured protocol to reach 5 mg/day by 4-5 months 1
- Alternative: Cyclophosphamide (IV or oral) plus glucocorticoids if rituximab unavailable 2, 3
For Non-organ-threatening GPA or MPA:
- First-line: Rituximab plus glucocorticoids 1
- Alternatives: Methotrexate or mycophenolate mofetil plus glucocorticoids 2, 3, 1
For Severe Renal Disease (creatinine >300-500 µmol/L):
- Consider adding plasma exchange to induction regimen for renal salvage 2, 1
- Evidence shows benefit for creatinine ≥500 µmol/L (5.7 mg/dL) 2
- Plasma exchange may also be considered for severe diffuse alveolar hemorrhage 3
For EGPA:
- Severe disease: Cyclophosphamide or rituximab plus glucocorticoids 1
- Non-severe disease: Mepolizumab, azathioprine, methotrexate, or mycophenolate mofetil 5
Glucocorticoid-Sparing Option:
- Avacopan (complement C5a receptor antagonist) may be used with rituximab or cyclophosphamide to substantially reduce glucocorticoid exposure 1
Step 3: Remission Maintenance
After achieving remission, continue maintenance therapy for at least 24-48 months: 3, 1
Preferred agents (in order):
- Rituximab (preferred, especially for relapsing disease) 1
- Azathioprine (level 1B evidence) 2
- Methotrexate 2
- Mycophenolate mofetil 2
- Leflunomide 2
Glucocorticoids: Taper to maintenance dose of ≤10 mg/day prednisolone during remission, with goal of discontinuation after 6-18 months depending on response 2
Step 4: Refractory or Relapsing Disease
For patients failing standard induction therapy or experiencing major relapse:
- Switch from cyclophosphamide to rituximab, or vice versa 3, 1
- Refer to expert vasculitis center immediately 2, 3
- Consider enrollment in clinical trials
- Alternative biologics: Infliximab, anti-thymocyte globulin (limited evidence) 2
- For persistent low-activity disease: Consider IVIG (check immunoglobulin levels first to avoid anaphylaxis in IgA deficiency or hyperviscosity) 2
Important Note: Rituximab achieved 91% remission rate (42/46 patients) within 6 months in refractory/relapsing AAV 2
Special Situations
Hepatitis C-Associated Cryoglobulinemic Vasculitis:
- Antiviral therapy is the primary treatment 2
Hepatitis B-Associated PAN:
- Combination of antiviral therapy, plasma exchange, and glucocorticoids 2
Essential (Non-viral) Cryoglobulinemic Vasculitis:
- Immunosuppressive therapy; manage with hepatologist 2
Giant Cell Arteritis/Takayasu Arteritis:
- High-dose glucocorticoids (1 mg/kg/day, max 60 mg) for remission induction 4
- Consider immunosuppressive agents as adjunctive therapy to reduce glucocorticoid exposure 4
- IV methylprednisolone for acute visual loss 4
Critical Monitoring and Safety
Ongoing Monitoring:
- Structured clinical assessment, urinalysis, and basic labs at every visit 2
- Do not use ANCA levels to guide treatment changes—use clinical assessment instead 3
- Monitor for treatment-related complications (infection, malignancy, metabolic effects)
Cyclophosphamide-Specific Precautions:
- Use Mesna for bladder protection 2
- Lifelong monitoring: Investigate any persistent unexplained hematuria immediately due to bladder cancer risk (can occur months to years after exposure) 2
- Risk highest in smokers 2
Rituximab-Specific Precautions:
- Check serum immunoglobulin levels before each course and in patients with recurrent infections 3
- Monitor for hypogammaglobulinemia
Glucocorticoid Prophylaxis:
- Bone protection therapy (calcium, vitamin D, bisphosphonates) for all patients 4, 6
- Monitor blood glucose regularly 2
Management Setting: